Coca-Cola

At 22x forward earnings Coca-Cola is priced like a growth company but it's growing organic revenue mostly through price hikes, not real volume expansion. When the pricing cycle normalizes, you're going to be left holding a 3% grower at a premium multiple. PepsiCo at least has Frito-Lay to anchor earnings.

Coke's international exposure cuts both ways. Emerging markets like India and Southeast Asia offer real volume growth potential as middle classes expand and out-of-home consumption rises. But the currency translation risk is significant and unpredictable — Nigeria naira and Argentine peso moves wiped out what were operationally strong quarters in those markets.

Coca-Cola has raised its dividend for 62 consecutive years, making it one of the longest streaks of any company in the S&P 500. With a current yield around 3% and a business that generates consistent free cash flow through virtually every economic cycle, this is a core holding for any income-focused portfolio. The dividend track record alone tells you everything about management's capital discipline.

Coca-Cola reported Q3 2024 organic revenue growth of 9% year-over-year, driven largely by price/mix rather than volume, which was roughly flat globally. Management reaffirmed full-year organic revenue guidance of 9-10% and raised comparable EPS guidance slightly. Currency headwinds remain a drag given significant exposure to markets like Egypt, Nigeria, and Argentina.

The IRS is pursuing a roughly $3.3 billion tax dispute against Coca-Cola related to how the company allocated profits from its foreign affiliates between 1996 and 2009. A US Tax Court ruled against Coke in 2020 and the case is still working through appeals. If the full liability sticks it would be a meaningful one-time hit to the balance sheet.

Does anyone have a strong view on whether the Fairlife acquisition is actually moving the needle for Coke's nutrition/dairy segment? I know it's been growing fast but I'm trying to understand if it changes the long-term story or if it's still just a small piece of the overall portfolio.

The Coca-Cola system's bottler network is a genuine competitive moat that nobody can replicate — 300+ bottling partners with established cold chain infrastructure in markets that would take decades and billions to rebuild from scratch. Monster and Celsius have distribution deals but nothing close to this scale. It's the ultimate barrier to entry.

Coca-Cola's pricing power is something else — they pushed through multiple rounds of price increases over the past two years and volume held up way better than most people expected. The away-from-home channel (restaurants, stadiums, cinemas) is fully recovered and growing again, which is pure margin. Hard to bet against a brand with this kind of consumer loyalty across 200+ countries.

GLP-1 drugs are a genuine long-term threat to Coca-Cola that the market keeps brushing off. If Ozempic and Wegovy adoption scales the way analysts are projecting, discretionary calorie consumption including sugary drinks takes a structural hit. Coke's zero-sugar line is growing but it's not a full offset.

What's the community's take on Coca-Cola's alcohol push — the Jack Daniel's and Bacardi canned cocktail partnerships plus the Topo Chico Hard Seltzer? Hard seltzer obviously went sideways for the whole industry but are the spirits-based RTDs a real growth avenue or another distraction?